Beneficial effects of rituximab therapy for systemic lupus erythematosus
- PMID: 17264461
- DOI: 10.1007/s12098-007-0033-y
Beneficial effects of rituximab therapy for systemic lupus erythematosus
Abstract
We report an 11-yr-old girl with systemic lupus erythematosus (SLE) with recurrent flares of skin and systemic manifestations, which were poorly controlled with conventional therapy. Treatment with rituximab, a monoclonal antibody against CD20, was associated with remission of symptoms and a steroid sparing effect that persisted for more than 9 months. Therapy with rituximab appears promising in subjects with SLE.
Similar articles
-
Management of therapy-resistant systemic lupus erythematosus with rituximab: report of a case and review of the literature.Acta Clin Belg. 2005 Mar-Apr;60(2):102-5. doi: 10.1179/acb.2005.019. Acta Clin Belg. 2005. PMID: 16082997 Review.
-
[Rituximab therapy for severe pediatric systemic lupus erythematosus].Zhonghua Er Ke Za Zhi. 2012 Sep;50(9):697-704. Zhonghua Er Ke Za Zhi. 2012. PMID: 23158822 Chinese.
-
Prompt remission of severe SLE with only three doses of rituximab infusion and low dose steroid: the first case report from Indonesia.Clin Rheumatol. 2009 Jun;28 Suppl 1:S27-30. doi: 10.1007/s10067-008-1069-8. Epub 2008 Dec 13. Clin Rheumatol. 2009. PMID: 19083076
-
[Rituximab (anti-CD20 monoclonal antibody) for refractory systemic lupus erythematosus: report of one case].Rev Med Chil. 2005 Jun;133(6):681-4. doi: 10.4067/s0034-98872005000600010. Epub 2005 Jul 22. Rev Med Chil. 2005. PMID: 16075133 Spanish.
-
Targeted B-cell depletion therapy in childhood-onset systemic lupus erythematosus: progress to date.Paediatr Drugs. 2007;9(6):371-8. doi: 10.2165/00148581-200709060-00004. Paediatr Drugs. 2007. PMID: 18052407 Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical